Skip to main content
. 2019 Feb 1;294(13):5008–5022. doi: 10.1074/jbc.RA118.004910

Figure 7.

Figure 7.

Anti-miR-144-3p reversed the suppression of RXFP1 in IPF lung fibroblasts. A and B, quantitative RT-PCR for miR-144-3p (A) or RXFP1 (B) from donor lung fibroblasts after transfection with a miR-144-3p antagonist (anti-miR-144-3p) and stimulation with TGFβ (p = 0.0001 for log-transformed data for miR-144-3p and RXFP1, by two-way ANOVA followed by Tukey's multiple comparisons test, n = 6). C, immunoblots for RXFP1 from donor and IPF lung fibroblasts following transfection with anti-miR-144-3p or scrambled controls (n = 3). D, densitometry of band intensity of RXFP1 normalized to β-actin from donor (E) and IPF (F) lung fibroblasts (p = ns for donor; p < 0.0001 for IPF, n = 3, data were analyzed by paired t test). E, Bio-Plex 200 multiplex analysis of bronchoalveolar lavage for Relaxin (n = 18 healthy controls and n = 126 IPF patients, p = not significant, Kolmogorov-Smirnov test).